Pasithea Therapeutics Corporation has released a corporate presentation outlining its ongoing development of PAS-004, a next-generation macrocyclic MEK inhibitor. According to the presentation, PAS-004 is designed to address limitations observed with earlier generation MEK inhibitors, with a focus on improved target binding, oral bioavailability, potency, and pharmacokinetic properties. The presentation also provides an overview of the company's pipeline, clinical trial progress, and strategic approach in the biotechnology sector. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.